Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Distinct transcription profiles of primary and secondary glioblastoma subgroups.

Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF.

Cancer Res. 2006 Jan 1;66(1):159-67.

2.

Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis.

Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, Taylor J, Hanash SM.

Cancer Res. 2001 Sep 15;61(18):6885-91.

3.

The definition of primary and secondary glioblastoma.

Ohgaki H, Kleihues P.

Clin Cancer Res. 2013 Feb 15;19(4):764-72. doi: 10.1158/1078-0432.CCR-12-3002. Epub 2012 Dec 3. Review.

4.

CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP.

Cancer Res. 2007 May 1;67(9):4010-5.

5.

Protein and mRNA levels of YKL-40 in high-grade glioma.

Kazakova MH, Staneva DN, Koev IG, Staikov DG, Mateva N, Timonov PT, Miloshev GA, Sarafian VS.

Folia Biol (Praha). 2014;60(6):261-7.

6.

HC gp-39 gene is upregulated in glioblastomas.

Shostak K, Labunskyy V, Dmitrenko V, Malisheva T, Shamayev M, Rozumenko V, Zozulya Y, Zehetner G, Kavsan V.

Cancer Lett. 2003 Aug 20;198(2):203-10.

7.

Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas.

Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, Konishi N.

Lab Invest. 2005 Feb;85(2):165-75.

8.

Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration.

Camby I, Belot N, Rorive S, Lefranc F, Maurage CA, Lahm H, Kaltner H, Hadari Y, Ruchoux MM, Brotchi J, Zick Y, Salmon I, Gabius HJ, Kiss R.

Brain Pathol. 2001 Jan;11(1):12-26.

PMID:
11145198
9.

Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas.

Tohma Y, Gratas C, Van Meir EG, Desbaillets I, Tenan M, Tachibana O, Kleihues P, Ohgaki H.

J Neuropathol Exp Neurol. 1998 Mar;57(3):239-45.

PMID:
9600216
10.

Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques.

Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helén PT, Schraml P, Kallioniemi OP, Kononen J.

Cancer Res. 2000 Dec 1;60(23):6617-22.

11.

YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.

Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD.

Clin Cancer Res. 2005 May 1;11(9):3326-34.

12.

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME.

Cancer Res. 2003 Oct 15;63(20):6613-25.

13.

Concurrent EGFR amplification and TP-53 mutation in glioblastomas.

Gil-Benso R, Lopez-Gines C, Benito R, López-Guerrero JA, Callaghan RC, Pellín A, Roldán P, Cerdá-Nicolas M.

Clin Neuropathol. 2007 Sep-Oct;26(5):224-31.

PMID:
17907599
14.

Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.

Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H.

Am J Pathol. 1999 Aug;155(2):387-94.

15.

High mobility group I-C protein in astrocytoma and glioblastoma.

Akai T, Ueda Y, Sasagawa Y, Hamada T, Date T, Katsuda S, Iizuka H, Okada Y, Chada K.

Pathol Res Pract. 2004;200(9):619-24.

PMID:
15497774
16.

Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.

Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF.

Cancer Res. 2010 Jan 15;70(2):453-62. doi: 10.1158/0008-5472.CAN-09-2189. Epub 2010 Jan 12.

17.

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects.

Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T.

Nat Genet. 2000 Sep;26(1):109-13.

PMID:
10973261
18.

Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.

Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, Hebbar A, Samuel C, Shetty M, Sreepathi HK, Santosh V, Hegde AS, Hegde S, Kondaiah P, Rao MR.

Oncogene. 2005 Oct 27;24(47):7073-83.

PMID:
16103883
19.

[Study on the expression of epidermal growth factor receptor and p53 in astrocytic gliomas: evidence for a distinct genetic pathway].

Dong L, Pu PY, Wang H, Wang GX, Kang CS, Jiao DR.

Zhonghua Bing Li Xue Za Zhi. 2006 Apr;35(4):232-6. Chinese.

PMID:
16776982
20.

Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.

Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H.

Acta Neuropathol. 1997 Oct;94(4):303-9.

PMID:
9341929

Supplemental Content

Support Center